No Influence of Dialysis on Mirtazapine – A Case Report

We examined the concentration of mirtazapine in human plasma during hemodialysis. We detected no significant change in the concentration of this antidepressant before and after the dialysis session. These data provide more security in the treatment of depressive patients who are hemodialysed.

References

• 1 Klaassen C-D. Principles of toxicology and treatment of poisoning. In: Brunton L, Lazo J, Parker K, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: The McGraw-Hill Companies 2005: 1739-1753
• 2 Murtagh F-E, Addington-Hall J, Higginson I-J. The prevalence of symptoms in end-stage renal disease: a systematic review.  Adv Chronic Kidney Dis. 2007;  14 82-99
• 3 Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum.  Ther Drug Monit. 2004;  26 78-84

Correspondence